Join Growin Stock Community!

康聯生醫6665.TW Overview

TW StockBiotech. & Medical
(No presentation for 6665)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

康聯生醫（6665）Overall Performance

康聯生醫（6665）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

康聯生醫（6665） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

康聯生醫（6665）Key Information

康聯生醫（6665）Profile

Healthconn Corp. provides customized disease prevention and health management services. The company offers personal and corporate health services; health promotion services, such as nutrition, exercise, stress, and sleep management services; and nutritional genomics, exercise prescriptions, lifestyle optimization, personalized health improvement plans, exclusive health manager services, and result-oriented effects. It also provides food safety detection, oncogene detection, bacteriological examination, molecular biology detection services, interdisciplinary intelligence, unprecedented health risk assessment, health management consulting, weight control, and healthconn awareness journey services. In addition, it offers Smart Health 365 Seamless Health Management, an all-year-round health management service. Healthconn Corp. was founded in 2009 and is based in Taipei, Taiwan.

康聯生醫（6665）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.37
PB Ratio
1.07
Price-to-FCF
2.02
METRIC
VALUE
vs. INDUSTRY
Gross Margin
18.68%
Net Margin
-0.44%
Revenue Growth (YoY)
-14.76%
Profit Growth (YoY)
-34.82%
3-Year Revenue Growth
3.40%
3-Year Profit Growth
-23.62%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.24
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.37
PB Ratio
1.07
Price-to-FCF
2.02
Gross Margin
18.68%
Net Margin
-0.44%
Revenue Growth (YoY)
-14.76%
Profit Growth (YoY)
-34.82%
3-Year Revenue Growth
3.40%
3-Year Profit Growth
-23.62%
default symbol

6665

康聯生醫

20.70D

0.48%

(0.00)

  • When is 6665's latest earnings report released?

    The most recent financial report for 康聯生醫 (6665) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6665's short-term business performance and financial health. For the latest updates on 6665's earnings releases, visit this page regularly.

  • How much cash does 6665 have?

    At the end of the period, 康聯生醫 (6665) held Total Cash and Cash Equivalents of 235.32M, accounting for 0.17 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 6665 go with three margins increasing?

    In the latest report, 康聯生醫 (6665) did not achieve the “three margins increasing” benchmark, with a gross margin of 16.61%%, operating margin of -0.87%%, and net margin of -0.62%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6665's profit trajectory and future growth potential.